Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation

Immunohorizons. 2023 May 1;7(5):299-306. doi: 10.4049/immunohorizons.2200062.

Abstract

TCR diversity measures are often used to understand the immune response in cancer. Traditional measures of diversity rely on bulk RNA sequencing (RNAseq) of the β-chain variable regions. However, the full αβ TCR repertoire is a combination of both the α- and β-chains, which are encoded by separate genes. In contrast with bulk RNAseq, single-cell RNAseq (scRNAseq) allows paired chain analyses, yielding a more accurate measure of the repertoire. Interestingly, ∼30% of mature peripheral T cells express multiple TCR alleles (e.g., two α-chains) and may exhibit dual Ag specificity. scRNAseq has become increasingly common, and data from both human and animal studies are publicly available. However, routine workflows discard secondary TCR alleles and focus on a single TCR clone per cell. This perspectives piece emphasizes why this may not be good practice and highlights unanswered questions in the field of T cell dual specificity.

MeSH terms

  • Animals
  • Base Sequence
  • Clone Cells
  • Humans
  • Neoplasms* / genetics
  • Receptors, Antigen, T-Cell, alpha-beta* / genetics
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell, alpha-beta